10x Genomics (TXG) Revenue (2018 - 2026)

10x Genomics has disclosed Revenue across 9 years of filings, most recently posting $151.0 million for Q2 2026.

• In Q2 2026, Revenue fell 12.65% year-over-year to $151.0 million; the TTM figure through Jun 2026 stood at $616.9 million (down 4.28% YoY), while the FY2025 annual figure was $642.8 million, up 5.25% from the prior year.
• Revenue came in at $151.0 million for Q2 2026 at 10x Genomics, roughly flat from $150.8 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $184.0 million in Q4 2023 to a low of $114.5 million in Q1 2022.
• Average Revenue over 5 years is $149.5 million, with a median of $151.3 million recorded in 2024.
• Year-over-year, Revenue gained 28.1% in 2023 and dropped 12.65% in 2026.
• Over 5 years, Revenue stood at $156.2 million in 2022, then rose by 17.76% to $184.0 million in 2023, then fell by 10.3% to $165.0 million in 2024, then increased by 0.61% to $166.0 million in 2025, then retreated by 9.03% to $151.0 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $151.0 million in Q2 2026, $150.8 million in Q1 2026, and $166.0 million in Q4 2025.